Abstract
Tumor heterogeneity has been established as the most crucial and independent prognostic and predictive target for the unmet need of the development of novel targeted drugs to successfully treat extensive genomic variability.
Colorectal cancer recommendation-based resection of liver metastasis represents a prime paradigm for the expansion of genome and transcriptome NGS. Indeed intratumor heterogeneity of primary and metastatic tumor completed with matched NGS of circulating cell-free DNA can reveal the spatiotemporal dynamics of CRC genomic long evolution.
Transcriptional and potentially clinical implications including discussion of new CRC oncotargets and drugs, as well as dynamic predictive biomarkers and expansion of available drug list are discussed.
(Citation: Gastric & Breast Cancer 2020; 15(1): 69-82)
|
